Showing 4251-4260 of 7767 results for "".
- New Time-Limited Double Allē Points Promotion Launched for Juvederm Usershttps://practicaldermatology.com/news/new-double-alle-points-promotion-for-juvederm-users/2461307/Consumers can earn double points in Allē, Allergan Aesthetics' loyalty rewards program, when treated with two or three syringes from the JUVÉDERM Collection of Fillers during the same visit. Allē points can be redeemed for future Allē-eligible treatments or products.&nb
- Online Extra: Let’s Talk About Truncal Acnehttps://practicaldermatology.com/news/online-extra-lets-talk-about-truncal-acne/2461304/While often trivialized as a cosmetic skin disease, acne is in fact an inflammatory skin condition with a complex pathogenesis associated with a significant physical and psychological burden. Approximately 50% of people with facial acne also have truncal acne manifesting on the back, shoulders, a
- Senté Launches Cysteamine HSA Pigment & Tone Correctorhttps://practicaldermatology.com/news/sente-launches-cysteamine-hsa-pigment-tone-corrector/2461301/Cysteamine HSA Pigment & Tone Corrector from Senté has launched to safely and effectively target pigmentation in all skin tones. The hydroquinone-free formula is safe for long-term use and formulated for all skin types, including dry or sensitive skin.
- Alma Launches the Alma Hybrid and Alma TED Systems in Canadahttps://practicaldermatology.com/news/alma-launches-the-alma-hybrid-and-alma-ted-systems-in-canada/2461298/Alma Hybrid and Alma TED systems are now commercially available in Canada, the company reports. Alma Hybrid, the first laser platform to include an ablative 10,600 nm (CO2) laser and a non-ablative 1570 nm laser for skin resurfacing that offers a comprehensive solution to utilize each b
- Aesthetics Biomedical Inc. Receives Third U.S. Patent for “Biological Preserving Composition and Methods of Use” for SoME Skincare Product Linehttps://practicaldermatology.com/news/aesthetics-biomedical-inc-receives-third-us-patent-for-biological-preserving-composition-and-methods-of-use-for-its-some-skincare-product-line/2461296/Aesthetics Biomedical Inc. scored its third U.S. patent for “biological preserving composition and methods of use” for its SoME skincare product line. The patent covers topical compositions for combining biologics with skincare preserving the exclusivity of SoME Skincar
- FDA Cracks Down on Three Companies for Selling Unapproved New Drugs for Mole and Skin Tag Removalhttps://practicaldermatology.com/news/fda-cracks-down-on-three-companies-for-selling-unapproved-new-drugs-for-mole-and-skin-tag-removal/2461294/The U.S. Food and Drug Administration issued three warning letters to three companies, including Amazon, for selling unapproved products for removing moles and skin tags, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). There are no FDA-appr
- Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directorshttps://practicaldermatology.com/news/third-harmonic-bio-appoints-thomas-m-soloway-to-its-board-of-directors/2461292/Thomas M. Soloway is now a member of Third Harmonic Bio, Inc.’s Board of Directors. Mr. Soloway brings more than 25 years of experience in the life sciences industry, with senior roles in strategy, operations, corporate finance and venture capital to the company,
- Lilly's Taltz Now Available in Citrate-Free Formulationhttps://practicaldermatology.com/news/lillys-taltz-now-available-in-citrate-free-formulation/2461291/Lilly's Taltz® (ixekizumab) is now available in a new, citrate-free formulation to reduce injection site pain. The new formulation, which was recently approved by The U.S. Food and Drug Administration in May 2022, includes the same active ingredient as the original formula
- Arcutis Completes Enrollment in Pivotal Phase 3 Roflumilast AD Trialhttps://practicaldermatology.com/news/arcutis-completes-enrollment-in-pivotal-phase-3-roflumilast-ad-trial/2461290/Arcutis Biotherapeutics, Inc. has completed enrollment of the last subject in its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- First Patient Enrolled in UNION Therapeutic’s Study of Orismilast MR tablet in ADhttps://practicaldermatology.com/news/first-patient-enrolled-in-union-therapeutics-study-of-orismilast-mr-tablet-in-ad/2461288/The first patient has been enrolled in ADESOS, a Phase 2b dose-finding study evaluating the safety and efficacy of UNION therapeutic’s orismilast MR tablet in adult patients with moderate to severe AD. The purpose of the study is to identify the appropria